STOCK TITAN
  1. Home
  2. News
  3. ICPT

Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Intercept Pharmaceuticals to participate in fireside chats and investor meetings at upcoming conferences
Positive
  • None.
Negative
  • None.

MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in fireside chats and investor meetings at the following upcoming investor conferences: 

  • The H.C. Wainwright 25th Annual Global Investment Conference, for which the chat will be taking place on September 11th, 2023, from 11:00-11:30am ET. 
  • The Baird Global Healthcare Conference, for which the chat will be taking place on September 13th, 2023, from 3:10-3:40pm ET. 

The fireside chats can be accessed on the investor page of Intercept’s website at http://ir.interceptpharma.com. 

About Intercept 
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on LinkedIn, Threads, and X (formerly Twitter).

Contact 
For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com


Stock ICPT logo
Intercept Pharmaceuticals, Inc.

NASDAQ:ICPT

ICPT Rankings

N/A Ranked by Market Cap
#562 Ranked by Stock Gains
N/A Ranked by Dividends

ICPT Latest News

Feb 29, 2024
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Nov 13, 2023
Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023
Nov 10, 2023
Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023
Nov 8, 2023
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Nov 8, 2023
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

ICPT Stock Data

794.69M
34.49M
3.13%
81.3%
24.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Morristown

About ICPT

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.